AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28741383 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dietary intervention)
Number of subjects: 163
Study 28741383 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet adherence
Number of subjects: 163
Study 26414973 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg melatonin before bedtime
Number of subjects: 48
Study 26414973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 25890276 — intervention group
Group type: EXPERIMENTAL
Intervention: FR trial (25% fluid intake)
Number of subjects: 11
Study 25890276 — intervention group
Group type: COMPARATOR
Intervention: HYD trial (full fluid intake)
Number of subjects: 11
Study 22846439 — intervention group
Group type: EXPERIMENTAL
Intervention: FRT patients
Number of subjects: 23
Study 22846439 — intervention group
Group type: COMPARATOR
Intervention: Evening chronotypes
Number of subjects: 23
Study 22087865 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib alone
Number of subjects: 25
Study 22087865 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib plus rifampicin
Number of subjects: 25
Study 22087865 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib plus dexamethasone
Number of subjects: 25
Study 22087865 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib alone, Bortezomib plus rifampicin, Bortezomib plus dexamethasone
Number of subjects: 25
Study 18071723 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted navigation (Group 2)
Number of subjects: 60
Study 18071723 — intervention group
Group type: COMPARATOR
Intervention: Conventional instrumented (Group 1)
Number of subjects: 60
Study 16828475 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG injection 3-4 hours earlier (Group C)
Number of subjects: 72
Study 16828475 — intervention group
Group type: COMPARATOR
Intervention: hCG injection at the same interval (Group B)
Number of subjects: 72
Study 16828475 — intervention group
Group type: COMPARATOR
Intervention: hCG injection with >or=47% immature oocytes (Group A)
Number of subjects: 72
Study 12752519 — intervention group
Group type: EXPERIMENTAL
Intervention: Myobloc (botulinum toxin type B)
Number of subjects: 0
Study 12752519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10767716 — intervention group
Group type: EXPERIMENTAL
Intervention: p53 and P-glycoprotein expression
Number of subjects: 111
Study 10767716 — intervention group
Group type: EXPERIMENTAL
Intervention: p53 and P-glycoprotein negative
Number of subjects: 111
Study 10767716 — intervention group
Group type: EXPERIMENTAL
Intervention: tumour size, p53, and P-gp expression
Number of subjects: 111
Study 10767716 — intervention group
Group type: EXPERIMENTAL
Intervention: overall survival
Number of subjects: 111
Study 10767716 — intervention group
Group type: EXPERIMENTAL
Intervention: disease-free status
Number of subjects: 111
Study 8581442 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold therapy (50 degrees F) for THA patients
Number of subjects: 74
Study 8581442 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold therapy (not specified for TKA)
Number of subjects: 74
Study 8581442 — intervention group
Group type: COMPARATOR
Intervention: Control (70 degrees F) for THA patients
Number of subjects: 74
Study 8581442 — intervention group
Group type: COMPARATOR
Intervention: Control for TKA patients
Number of subjects: 74
Study 8581442 — intervention group
Group type: COMPARATOR
Intervention: Cold therapy and Control for both THA and TKA patients
Number of subjects: 74
Study 2478415 — intervention group
Group type: EXPERIMENTAL
Intervention: Local prostaglandin (PG) F2 alpha and systemic PG E2 application
Number of subjects: 71
Study 2478415 — intervention group
Group type: COMPARATOR
Intervention: Usual surgical technique
Number of subjects: 71
Study 790914 — intervention group
Group type: EXPERIMENTAL
Intervention: 15(R)‐15 methyl‐PGE2
Number of subjects: 0
Study 790914 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2
Number of subjects: 0
Study 790914 — intervention group
Group type: EXPERIMENTAL
Intervention: Naturally occurring prostaglandins (PGA2, PGB1, PGB2)
Number of subjects: 0
Study 790914 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic analogues of prostaglandin E2 (15‐methyl and 16,16‐dimethyl)
Number of subjects: 0
Study 31731651 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (D3)
Number of subjects: 67
Study 31731651 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcifediol (25D3)
Number of subjects: 67
Study 31731651 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (both D3 and 25D3)
Number of subjects: 67
Study 29136444 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary nail fixation (nail group; n=161)
Number of subjects: 321
Study 29136444 — intervention group
Group type: COMPARATOR
Intervention: Locking plate fixation (plate group; n=160)
Number of subjects: 321
Study 25957058 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (EXE) for 6 weeks
Number of subjects: 23
Study 25957058 — intervention group
Group type: COMPARATOR
Intervention: Control (CONT)
Number of subjects: 23
Study 24364364 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmony@Home intervention
Number of subjects: 461
Study 24364364 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 461
Study 24364364 — intervention group
Group type: COMPARATOR
Intervention: Third active intervention
Number of subjects: 461
Study 22100194 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan-based therapy
Number of subjects: 2049
Study 22100194 — intervention group
Group type: COMPARATOR
Intervention: Non-ARB-based standard therapy
Number of subjects: 2049
Study 19220756 — intervention group
Group type: EXPERIMENTAL
Intervention: R-137696 2 mg t.i.d. for 4 weeks
Number of subjects: 53
Study 19220756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 17224029 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully rough implants (FR)
Number of subjects: 26
Study 17224029 — intervention group
Group type: COMPARATOR
Intervention: Partially rough implants (PR)
Number of subjects: 26
Study 15222523 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 ml of 0.5% hyperbaric bupivacaine + 20 mg of fentanyl (Group F)
Number of subjects: 40
Study 15222523 — intervention group
Group type: COMPARATOR
Intervention: 4 ml of 0.5% hyperbaric bupivacaine + 0.4 ml normal saline (Group S)
Number of subjects: 40
Study 12667371 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia group (local mild hypothermia at 6 degrees C for 48 hours)
Number of subjects: 40
Study 12667371 — intervention group
Group type: COMPARATOR
Intervention: Routine group (dehydrant, antihypertensive agent, etc.)
Number of subjects: 40
Study 9689720 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 20
Study 9689720 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 20
Study 8526196 — intervention group
Group type: COMPARATOR
Intervention: Folinic acid + fluorouracil (arm A)
Number of subjects: 71
Study 8526196 — intervention group
Group type: EXPERIMENTAL
Intervention: Folinic acid + fluorouracil + 4-epidoxorubicin (arm B)
Number of subjects: 71
Study 1958119 — intervention group
Group type: EXPERIMENTAL
Intervention: Linsidomine (0.8 mg)
Number of subjects: 80
Study 1958119 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin (0.15 mg)
Number of subjects: 80
Study 6786134 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate used alone for induction
Number of subjects: 3
Study 6786134 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate combined with fentanyl
Number of subjects: 3
Study 6786134 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate (10-20 micrograms/kilogramme bodyweight/minute) combined with fentanyl and muscle relaxants
Number of subjects: 3
Study 31093795 — intervention group
Group type: EXPERIMENTAL
Intervention: Submental intubation
Number of subjects: 32
Study 31093795 — intervention group
Group type: COMPARATOR
Intervention: Elective tracheostomy
Number of subjects: 32
Study 28704258 — intervention group
Group type: EXPERIMENTAL
Intervention: STAND‐SIT (alternating standing and sitting every 30 minutes)
Number of subjects: 25
Study 28704258 — intervention group
Group type: COMPARATOR
Intervention: SIT (continuous sitting condition)
Number of subjects: 25
Study 26109173 — intervention group
Group type: EXPERIMENTAL
Intervention: Active case finding (ACF) program including provider-initiated home visits of all new sputum smear positive TB patients.
Number of subjects: 0
Study 23786619 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 2-hexyldecanol
Number of subjects: 110
Study 23786619 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 110
Study 21281671 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity program (duration: 9 months)
Number of subjects: 59
Study 19815152 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of ibuprofen 1 hour before separator placement, 400 mg at 3 hours after placement, and 400 mg at 7 hours after placement (Group A)
Number of subjects: 0
Study 19815152 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo at 1 hour before separator placement, 400 mg of ibuprofen at 3 hours and 7 hours after placement (Group B)
Number of subjects: 0
Study 19815152 — intervention group
Group type: COMPARATOR
Intervention: Placebo at 1 hour, 3 hours, and 7 hours after separator placement (Group C)
Number of subjects: 0
Study 16762579 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-Hib vaccine
Number of subjects: 200
Study 16762579 — intervention group
Group type: COMPARATOR
Intervention: DTaP-IPV plus Hib vaccine
Number of subjects: 200
Study 16762579 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 200
Study 15265815 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling training for doctors in intervention centres
Number of subjects: 2460
Study 15265815 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 2460
Study 11500337 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antimicrobial prophylaxis (gentamicin/colistin/vancomycin 2% in Orabase, every 6 h)
Number of subjects: 226
Study 11500337 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antimicrobial prophylaxis
Number of subjects: 226
Study 11500337 — intervention group
Group type: COMPARATOR
Intervention: Control group A (placebo)
Number of subjects: 226
Study 11500337 — intervention group
Group type: COMPARATOR
Intervention: Control group B (placebo)
Number of subjects: 226
Study 11500337 — intervention group
Group type: EXPERIMENTAL
Intervention: Study group (topical prophylaxis)
Number of subjects: 226
Study 10204257 — intervention group
Group type: EXPERIMENTAL
Intervention: Curosurf prophylaxis
Number of subjects: 28
Study 10204257 — intervention group
Group type: COMPARATOR
Intervention: Rescue treatment
Number of subjects: 28
Study 7855225 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 mg nicotine
Number of subjects: 12
Study 7855225 — intervention group
Group type: COMPARATOR
Intervention: 0.8 ml saline
Number of subjects: 12
Study 7855225 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 12
Study 2660902 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation
Number of subjects: 85
Study 2660902 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow transplantation
Number of subjects: 85
Study 2660902 — intervention group
Group type: COMPARATOR
Intervention: Intensive sequential chemotherapy
Number of subjects: 85
Study 30704700 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI) 100/25 μg
Number of subjects: 0
Study 30704700 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 0
Study 28103612 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg per day)
Number of subjects: 256
Study 28103612 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib (250 mg per day)
Number of subjects: 256
Study 26556084 — intervention group
Group type: EXPERIMENTAL
Intervention: CCFES
Number of subjects: 60
Study 26556084 — intervention group
Group type: COMPARATOR
Intervention: NMES
Number of subjects: 60
Study 24043283 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (1 mg/kg, then 0.6 mg/kg for 4 more days)
Number of subjects: 200
Study 24043283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 24043283 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 200
Study 24043283 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 200
Study 21953143 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with Rituximab
Number of subjects: 163
Study 21953143 — intervention group
Group type: COMPARATOR
Intervention: Active disease
Number of subjects: 163
Study 21953143 — intervention group
Group type: EXPERIMENTAL
Intervention: MMP‐3
Number of subjects: 163
Study 17884176 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Cognitive Therapy (MBCT)
Number of subjects: 0
Study 17884176 — intervention group
Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 0
Study 16792244 — intervention group
Group type: EXPERIMENTAL
Intervention: NiTi springs
Number of subjects: 12
Study 16792244 — intervention group
Group type: COMPARATOR
Intervention: Elastomeric chains
Number of subjects: 12
Study 14606504 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microg teriparatide
Number of subjects: 51
Study 14606504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 11092169 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine, adenosine-receptor-agonists, and dipyridamole prior to coronary angioplasty
Number of subjects: 0
Study 11092169 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil, an activator of the ATP-sensitive potassium channel (K-ATP channel)
Number of subjects: 0
Study 11092169 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide (sulfonylurea drug therapy)
Number of subjects: 0
Study 9096687 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose mitoxantrone (80 mg/m2 on day 2) with cytarabine (3 g/m2 on days 1-5)
Number of subjects: 54
Study 9096687 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose mitoxantrone (12 mg/m2 on days 1-3) with cytarabine (3 g/m2 on days 1-5)
Number of subjects: 54
Study 9096687 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose mitoxantrone
Number of subjects: 54
Study 9096687 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose mitoxantrone
Number of subjects: 54
Study 8415897 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg paroxetine per day
Number of subjects: 160
Study 8415897 — intervention group
Group type: COMPARATOR
Intervention: 150 mg amitriptyline per day
Number of subjects: 160
Study 3003728 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 36
Study 3003728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 3003728 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (injection)
Number of subjects: 36
Study 30927744 — intervention group
Group type: EXPERIMENTAL
Intervention: Uninterrupted sleep (US)
Number of subjects: 42
Study 30927744 — intervention group
Group type: COMPARATOR
Intervention: Forced awakenings (FA)
Number of subjects: 42
Study 29096426 — intervention group
Group type: EXPERIMENTAL
Intervention: RG7342 (0.06-1.2 mg)
Number of subjects: 37
Study 29096426 — intervention group
Group type: EXPERIMENTAL
Intervention: RG7342 (1.2 mg)
Number of subjects: 37
Study 29096426 — intervention group
Group type: EXPERIMENTAL
Intervention: RG7342 (0.6 mg fasting)
Number of subjects: 37
Study 29096426 — intervention group
Group type: EXPERIMENTAL
Intervention: RG7342 (0.9 mg fed)
Number of subjects: 37
Study 29096426 — intervention group
Group type: EXPERIMENTAL
Intervention: RG7342
Number of subjects: 37
Study 29096426 — intervention group
Group type: EXPERIMENTAL
Intervention: RG7342 (MTD fasting, fed)
Number of subjects: 37
Study 29096426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 27130646 — intervention group
Group type: EXPERIMENTAL
Intervention: Hernia repair combined with abdominoplasty
Number of subjects: 111
Study 27130646 — intervention group
Group type: COMPARATOR
Intervention: Isolated incisional hernia repair
Number of subjects: 111
Study 24612661 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib added to standard treatment
Number of subjects: 433
Study 24612661 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 433
Study 22511135 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation +10 cm H2O
Number of subjects: 16
Study 22511135 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation +15 cm H2O
Number of subjects: 16
Study 22511135 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation +5 cm H2O
Number of subjects: 16
Study 22511135 — intervention group
Group type: COMPARATOR
Intervention: Conventional mechanical ventilation
Number of subjects: 16
Study 20586556 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosomatic intervention
Number of subjects: 238
Study 20586556 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 238
Study 17224119 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrylic lenses
Number of subjects: 23
Study 17224119 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone lenses
Number of subjects: 23
Study 17224119 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel lenses
Number of subjects: 23
Study 17224119 — intervention group
Group type: EXPERIMENTAL
Intervention: Sharp-edge designs
Number of subjects: 23
Study 17224119 — intervention group
Group type: COMPARATOR
Intervention: Rounded-edge designs
Number of subjects: 23
Study 15846273 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 202
Study 15846273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study 12095721 — intervention group
Group type: EXPERIMENTAL
Intervention: PCCP
Number of subjects: 71
Study 12095721 — intervention group
Group type: COMPARATOR
Intervention: DHS
Number of subjects: 71
Study 9867078 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 microg/kg rhIGF-I
Number of subjects: 7
Study 9867078 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microg/kg rhIGF-I
Number of subjects: 7
Study 9867078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 8561269 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical aminosidine ointment (twice a day for two weeks)
Number of subjects: 251
Study 8561269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study 2520622 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetropium bromide 50 mg t.d.s. for 1 month
Number of subjects: 40
Study 2520622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30061088 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 1505
Study 30061088 — intervention group
Group type: COMPARATOR
Intervention: Comparators
Number of subjects: 1505
Study 27737654 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine third trimester ultrasonography (two routine ultrasound examinations at 28-30 weeks and 34-36 weeks)
Number of subjects: 15000
Study 27737654 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonography based on medical indication (control condition)
Number of subjects: 15000
Study 27737654 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic evaluation measuring costs from a societal perspective and quality of life using EQ-5D-5L
Number of subjects: 15000
Study 27737654 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative sub-study exploring ethical considerations
Number of subjects: 15000
Study 25631687 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E‐treated highly cross‐linked polyethylene (HXLPE) liner (vitamin‐e group, n=25)
Number of subjects: 51
Study 25631687 — intervention group
Group type: COMPARATOR
Intervention: Standard HXLPE liner (control group, n=26)
Number of subjects: 51
Study 23398528 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy diet
Number of subjects: 200
Study 23398528 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 200
Study 21211010 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone ventilation
Number of subjects: 1675
Study 18712776 — intervention group
Group type: EXPERIMENTAL
Intervention: CACE modelling
Number of subjects: 0
Study 18712776 — intervention group
Group type: EXPERIMENTAL
Intervention: Covariates predicting compliance
Number of subjects: 0
Study 18712776 — intervention group
Group type: COMPARATOR
Intervention: Intention-to-treat (ITT) analysis
Number of subjects: 0
Study 16470370 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully automatic diagnostic system
Number of subjects: 20
Study 16470370 — intervention group
Group type: COMPARATOR
Intervention: Visual inspection by experts
Number of subjects: 20
Study 16470370 — intervention group
Group type: COMPARATOR
Intervention: Visual inspection by beginners
Number of subjects: 20
Study 12775666 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted learning (CAL) program
Number of subjects: 67
Study 12775666 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CAL program)
Number of subjects: 67
Study 11829370 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation Training (PMRT)
Number of subjects: 8
Study 11829370 — intervention group
Group type: COMPARATOR
Intervention: Oral anti-emetics (maxolon)
Number of subjects: 8
Study 9345797 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior repositioning splint worn 24 hours a day
Number of subjects: 0
Study 9345797 — intervention group
Group type: COMPARATOR
Intervention: Anterior repositioning splint worn during the day or at night
Number of subjects: 0
Study 7802732 — intervention group
Group type: EXPERIMENTAL
Intervention: Screened group (chest x-ray and sputum cytology every 4 months)
Number of subjects: 10111
Study 7802732 — intervention group
Group type: COMPARATOR
Intervention: Control group (annual chest x-ray and cytology recommended)
Number of subjects: 10111
Study 7802732 — intervention group
Group type: EXPERIMENTAL
Intervention: Screened group
Number of subjects: 10111
Study 7802732 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10111